Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
517
datasets available to search
ShareScore release 0.9.0
Dataset results
517 results for “Checkpoint inhibitors”
Dataset related to article "18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors "
<p>This record contains raw data related to article 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors</p> <p>Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with <sup>18</sup>F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before immunotherapy, 8 weeks and 17 weeks after administration of either nivolumab or pembrolizumab. The median follow-up was 19 months. Best clinical response was complete response (CR) in 26 patients, partial response (PR) in 5 patients, stable disease (SD) in 8 patients, and progression disease (PD) in 4 patients. At the early assessment, Deauville Score (DS) resulted significantly different in responder group compared to nonresponders. SUVmax was significantly lower in responders, while there was no relevant modification in the tumor burden. At interim evaluation, DS well differentiated responder group. A significant decrease in glucose metabolism and tumor burden parameters was observed in responder patients, who presented with a longer progression-free survival then nonresponders. <sup>18</sup>F-FDG PET/CT provides a reliable indication of treatment response under checkpoints inhibitors, even at an early assessment.</p>
Oncolytic virus M1 functions as a bi-functional checkpoint inhibitor to enhance the antitumor activity of DC vaccine
GEO Series GSE222080. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Transcriptomic and metabolic effect of immune checkpoint inhibitors on cellular components in renal cell tumor microenvironment and in Sunitinib resistant renal cell carcinoma [II]
GEO Series GSE226967. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRASG12C-mutant NSCLC for Immune Checkpoint Blockade
GEO Series GSE315010. Homo sapiens; Mus musculus. 44 samples. Type: Expression profiling by high throughput sequencing.
Clonal CD8 T cells orchestrate arrhythmogenic inflammation in immune checkpoint inhibitor-associated myocarditis
GEO Series GSE298932. Mus musculus. 2 samples. Type: Other.
Propranolol reduces sarcoma growth and enhances the response to anti-CTLA4 checkpoint inhibitor therapy by modulating the tumor microenvironment
GEO Series GSE174645. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies
GEO Series GSE241125. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
SLC6A3 Dopaminergic Signaling Subverts Spliceosomal Fidelity to Promote Immune Checkpoint Inhibitor Resistance in Clear Cell Renal Cell Carcinoma [2]
GEO Series GSE316470. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Gene expression profiles of melanoma tumor samples from patients treated with checkpoint inhibitors
GEO Series GSE122222. Mus musculus; Homo sapiens. 22 samples. Type: Expression profiling by array.
A β-1,3/1,6-glucan from Durvillaea Antarctica enhances anti-tumor effects of immune checkpoint inhibitor antibodies II
GEO Series GSE242577. Mus musculus. 15 samples. Type: Expression profiling by high throughput sequencing.
Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer [CHIP-seq]
GEO Series GSE196324. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
SLC6A3 Dopaminergic Signaling Subverts Spliceosomal Fidelity to Promote Immune Checkpoint Inhibitor Resistance in Clear Cell Renal Cell Carcinoma [1]
GEO Series GSE316468. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Neurological complications in patient treated with checkpoint inhibitors
<p>Neurological immune-related adverse events (nirAEs) are rare toxicities of immune-checkpoint inhibitors (ICI). With the increase of ICI oncological indications, their incidence is growing. Their recognition and management remain nevertheless challenging.</p> <p>A national, web-based database was built to collect cases of neurological symptoms in patients receiving ICI and not attributable to other causes after an adequate workup.</p> <p>We identified 27 patients who developed nirAEs (20 males, median age 69 years). Patients received anti-PD1/PDL1 (78%), anti-CTLA4 (4%), or both (19%). Most common cancers were melanoma (30%) and non-small cell lung cancer (26%). Peripheral nervous system was mostly affected (78%). Median time to onset was 43.5 days and was shorter for peripheral versus central nervous system toxicities (36 versus 144.5 days, p = 0.045). Common manifestations were myositis (33%), inflammatory polyradiculoneuropathies (33%), and myasthenia gravis (19%), alone or in combination, but the spectrum of diagnoses was broad. Most patients received first-line glucocorticoids (85%) or IVIg (15%). Seven patients (26%) needed second-line treatments. At last follow-up, four (15%) patients were deceased (encephalitis, 1; myositis/myasthenia with concomitant myocarditis, 2; acute polyradiculoneuropathy, 1), while seven (26%) had a complete remission, eight (30%) partial improvement, and six (22%) stable/progressing symptoms. ICI treatment was discontinued in most patients (78%).</p> <p>Neurological irAEs are rare but potentially fatal. They primarily affect neuromuscular structures but encompass a broad range of presentations. A prompt recognition is mandatory to timely withheld immunotherapy and administrate glucocorticoids. In corticoresistant or severely affected patients, second-line treatments with IVIg or plasmapheresis may result in additional benefit.</p>
Dataset related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors"
<p>This record contains raw data related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors"</p> <p>Risk factors for hepatic immune-related adverse events (HIRAEs) in patients with advanced/unresectable hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are unclear. We investigated: (i) clinical and morpho-pathological predictors of HIRAEs in 27 pretreatment tumor specimens, including surrogate biomarkers of the HCC immune class (based on intratumoral tertiary lymphoid structures, and glutamine synthase, CD3, and CD79 expression); and (ii) the relationship between HIRAE onset and subsequent treatment outcomes. Fifty-eight patients were included-20 (34%) received ICIs alone, and 38 (66%) received ICIs plus targeted agents as first- or further-line treatment. After a median time of 0.9 months (range, 0.4-2.7), nine patients (15.5%) developed grade ≥ 3 hepatitis, which was significantly associated with higher baseline ALT levels (<em>p</em> = 0.037), and an infectious HCC etiology (<em>p</em> = 0.023). ICIs were safely resumed in six out of nine patients. Time to treatment failure (TTF) was not significantly different in patients developing grade ≥ 3 hepatitis vs. lower grades (3.25 vs. 3.91 months, respectively; <em>p</em> = 0.81). Biomarker surrogates for the HCC immune class were not detected in patients developing grade ≥ 3 hepatitis. Grade ≥ 3 hepatitis has a benign course that does not preclude safe ICI reintroduction, without any detrimental effect on TTF.</p>
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
<p>This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients.</p> <p><strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer patient-derived organoid (BPTO.95 #1 and #2) both at the untreated or Parental state and post resistance to Palbociclib</strong>.</p> <p>Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (10-12 months for PDO). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R PDOs were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.</p>
Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer.
GEO Series GSE196325. Mus musculus; Homo sapiens. 59 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Dataset related to article "Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I"
<p>This record contains raw data (metabolomic and RNASeq data) related to the article: "Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I"</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.